Dilana E Staudt, Heather C Murray, David A Skerrett-Byrne, Nathan D Smith, M Fairuz B Jamaluddin, Richard G S Kahl, Ryan J Duchatel, Zacary P Germon, Tabitha McLachlan, Evangeline R Jackson, Izac J Findlay, Padraic S Kearney, Abdul Mannan, Holly P McEwen, Alicia M Douglas, Brett Nixon, Nicole M Verrills, Matthew D Dun
Global high-throughput phosphoproteomic profiling is increasingly being applied to cancer specimens to identify the oncogenic signaling cascades responsible for promoting disease initiation and disease progression; pathways that are often invisible to genomics analysis. Hence, phosphoproteomic profiling has enormous potential to inform and improve individualized anti-cancer treatment strategies. However, to achieve the adequate phosphoproteomic depth and coverage necessary to identify the activated, and hence, targetable kinases responsible for driving oncogenic signaling pathways, affinity phosphopeptide enrichment techniques are required and often coupled with offline high-pressure liquid chromatographic (HPLC) separation prior to nanoflow liquid chromatography-tandem mass spectrometry (nLC-MS/MS)...
December 19, 2022: Clinical Proteomics